TOVX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Theriva Biologics's net margin of -49.65%. Theriva Biologics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 79.7%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Theriva Biologics's net income of -$4.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus 0.13x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -- compared to Theriva Biologics's net margin of --. Theriva Biologics's return on equity of -- beat Nanoviricides's return on equity of --.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 556.57%. Given that Nanoviricides has higher upside potential than Theriva Biologics, analysts believe Nanoviricides is more attractive than Theriva Biologics.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Theriva Biologics's net income of -$4.4M is lower than Nanoviricides's net income of -$2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Theriva Biologics's net margin of --. Theriva Biologics's return on equity of -- beat Oragenics's return on equity of --.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 461.48%. Given that Theriva Biologics has higher upside potential than Oragenics, analysts believe Theriva Biologics is more attractive than Oragenics.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Theriva Biologics's net income of -$4.4M is lower than Oragenics's net income of -$3.3M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus 1.11x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Theriva Biologics's net margin of -2357.27%. Theriva Biologics's return on equity of -- beat Palatin Technologies's return on equity of --.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 466.04%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1484.07%. Given that Palatin Technologies has higher upside potential than Theriva Biologics, analysts believe Palatin Technologies is more attractive than Theriva Biologics.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Theriva Biologics's net income of -$4.4M is lower than Palatin Technologies's net income of -$2.4M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.